UM Miller School of Medicine: Prurigo Nodularis Treatment Effective in Phase 3 Trial
December 08, 2023
December 08, 2023
MIAMI, Florida, Dec. 8 (TNSres) -- The University of Miami's Miller School of Medicine issued the following news:
By Rochelle Broder-Singer
Shortly after the FDA approved the first systemic therapy for the chronic severe itch of prurigo nodularis (PN), researchers have demonstrated the effectiveness of a second systemic treatment in a phase 3 clinical trial.
Gil Yosipovitch, M.D., professor in the Dr. Phillip Frost Department of Dermatology and Cutaneo . . .
By Rochelle Broder-Singer
Shortly after the FDA approved the first systemic therapy for the chronic severe itch of prurigo nodularis (PN), researchers have demonstrated the effectiveness of a second systemic treatment in a phase 3 clinical trial.
Gil Yosipovitch, M.D., professor in the Dr. Phillip Frost Department of Dermatology and Cutaneo . . .